GlobeNewswire

Teledyne Optech Titan lidar enables discovery of extended Mayan ruins in Guatemala

Dela

VAUGHAN, Ontario, Feb. 06, 2018 (GLOBE NEWSWIRE) -- Teledyne Optech's Titan sensor was used by the University of Houston's National Center for Airborne Laser Mapping (NCALM) to reveal extensive Mayan ruins in Guatemala. Lidar technology was able to identify hundreds of previously unknown structures, including raised highways, and complex irrigation and terracing systems.

After the collapse of the Mayan civilization, their cities and monuments were quickly covered by thick rainforest, hiding the ancient civilization from airborne observation and making it very difficult to survey on foot. Flying high above the rainforest, the Titan's lasers penetrated the canopy to collect almost a million data points per second from the forest floor, giving archaeologists a "bare earth" view of the structures underneath. Having covered 2,100 km2, the Titan's data revealed massive amounts of ruins hidden below the forest, showing that their urban centers were significantly larger than archaeologists had previously thought.

"We are incredibly proud and excited that our award winning Titan multispectral lidar sensor has contributed to this spectacular discovery," said Michel Stanier, EVP and General Manager of Teledyne Optech. "The Titan's ability to strip away overlying vegetation and map wide areas very quickly and accurately makes it an important tool for archaeologists, and we expect to see many more discoveries coming from it and our other airborne laser terrain mappers."

The Optech Titan is the first commercial multi-spectral lidar sensor to incorporate 3 independent laser wavelengths into a single sensor design, with beams at 532, 1064, and 1550 nm (0.5/1.0/1.5 microns) and a ground sampling rate of 300 kHz per beam. Because Titan uses both green and infrared channels, it is capable of simultaneous water depth mapping and high-precision 900-kHz topography. Titan can also be used for purposes such as vegetative and forestry applications, which require multiple wavelengths for improved classification accuracy and carbon credit counting initiatives.

As featured in National Geographic's Lost Treasures of the Maya Snake Kings, more information about which can be found at www.natgeotv.com. Find out more at www.teledyneoptech.com

About Teledyne Optech
Teledyne Optech is the world leader in high-accuracy lidar 3D survey systems, integrated cameras, and productivity-enhancing workflows. With operations and staff worldwide, Teledyne Optech offers both standalone and fully integrated lidar and camera solutions for airborne mapping, airborne lidar bathymetry, mobile mapping, terrestrial laser scanning, mine cavity monitoring, and industrial process control, as well as space-proven sensors. Teledyne Optech supports its clients with an around-the-clock team, on-site service, and regular efficiency enhancements to the workflow of its integrated systems. Accuracy and productivity matter!

Photos accompanying this announcement are available at http://www.globenewswire.com/NewsRoom/AttachmentNg/e8d3ebaf-2629-4295-a5e1-4ca140eb1cac and http://www.globenewswire.com/NewsRoom/AttachmentNg/a4695edf-3ff1-4a4f-bb47-26bb74eaa2e1

For further information, please contact your Regional Sales Manager or:

Wayne Szameitat
International Sales Manager

 
Teledyne Optech 
300 Interchange Way
Vaughan, Ontario, Canada L4K 5Z8

+1 905 660 0808
inquiries@teledyneoptech.com
www.teledyneoptech.com

 

 



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Teledyne DALSA via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Oboya signs a cooperation agreement with Gaia regarding biomaterials13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") has signed an important and long-term cooperation agreement on environmentally friendly biomaterials with Gaia Biomaterials AB ("Gaia") in Helsingborg, Sweden. The agreement means that Oboya uses Gaias biomaterials for the production and development of environmentally friendly cultivation products for the cultivation industry. Oboya has been actively involved in innovation, environmental and sustainability issues in recent years, and our goal is to encourage environmental and sustainability in the cultivation industry by offering environmentally friendly cultivation products to our customers. Oboya believes that the use of biomaterials will be important for success in the conversion to a fossil-free cultivation industry worldwide. The cooperation agreement means that Oboya uses Gaias biomaterials in its production and that through Gaias expertise we can develop new environmentally friendly cultivation products. Gaias biomaterials are bi

Oboya tecknar ett samarbetsavtal med Gaia avseende biomaterial13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") har tecknat ett viktigt och långsiktigt samarbetsavtal avseende miljövänligt biomaterial med Gaia Biomaterials AB ("Gaia") i Helsingborg, Sverige. Avtalet innebär att Oboya använder Gaias biomaterial för tillverkning och utveckling av miljövänliga odlingsprodukter till odlingsindustrin. Oboya har under de senaste åren arbetat aktivt med innovation, miljö- och hållbarhetsfrågor och vårt mål är att främja miljö och hållbarhet inom odlingsindustrin genom att erbjuda miljövänliga odlingsprodukter till våra kunder. Oboya anser att användningen av biomaterial kommer att vara viktigt för framgång i omställningen till en fossilfri odlingsindustri världen över. Samarbetsavtalet innebär att Oboya använder Gaias biomaterial i sin produktion och att vi genom Gaias kompetens kan utveckla nya miljövänliga odlingsprodukter. Gaias biomaterial är biologiskt nedbrytbart, komposterbart samt ger upp till 80 % lägre koldioxidutsläpp vid förbränning jämfört

Stillfront: Simutronics reclaims publishing services10.12.2018 14:11Pressmeddelande

PRESS RELEASE December 10, 2018 Simutronics reclaims the publishing services for SIEGE: Titan Wars globally except China Simutronics Corp, a studio within Stillfront Group AB, has ended a co-publishing agreement regarding the mobile game SIEGE: Titan Wars with New York based publishing partner Tilting Point. According to a new agreement, Tilting Point will continue to provide publishing services and market the game in China but Simutronics will run the publishing services and marketing globally from the Group going forward. Simutronics is a leading developer of online roleplaying and mobile games such as DragonRealms, GemStone IV and Lara Croft Relic Run, the latter with more than 23 million downloads. Tilting Point is a new-generation games partner that provides top development studios with expert resources, services, and operational support to optimize high quality live games for success. "I am very pleased to continue the partnership with Tilting Point for the Chinese market as this

Stillfront: Simutronics återtar förläggartjänster10.12.2018 14:11Pressmeddelande

PRESSMEDDELANDE 2018-12-10 Simutronics återtar förläggartjänster för SIEGE: Titan Wars globalt med undantag för Kina Simutronics, en studio inom Stillfront Group, har avslutat ett medförläggaravtal avseende mobilspelet SIEGE: Titan Wars med den New York-baserade förläggarpartnern Tilting Point. Enligt ett nytt avtal kommer Tilting Point fortsatt att tillhandahålla förläggartjänster och marknadsföring av spelet i Kina men på global nivå kommer Simutronics att ansvara för förläggartjänster och marknadsföring av spelet från gruppen. Simutronics är en ledande utvecklare av rollspel och mobila spel som till exempel DragonRealms, GemStone IV och Lara Croft Relic Run, den sistnämnda med mer än 23 miljoner nedladdningar. Tilting Point är den nya generationens spelbolagspartner som förser ledande utvecklingsstudios med expertis, tjänster och operationell support för att optimera högkvalitativa livespel framgångsrikt. "Jag är mycket nöjd över det fortsatta partnerskapet med Tilting Point för den

Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II study of APR 2462.12.2018 18:00Pressmeddelande

STOCKHOLM, December 2, 2018. Karolinska Development's portfolio company Aprea Therapeutics today presented positive clinical results for its drug candidate APR 246 at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego, US. An Overall Response Rate of 95% and a Complete Remission (CR) rate of 70% were achieved in an ongoing Phase I/II combination study of APR 246 and azacitidine (AZA) for the treatment of TP53 mutated Myelodysplastic Syndrome (MDS). No dose-limiting toxicities have been observed. Based on these encouraging data, Aprea intends to progress APR 246 into a Phase III study in the near future. The results presented at the ASH meeting is based on 20 patients with TP53 mutated MDS. The overall response rate was 95%, and 14 (70%) patients achieved a complete remission at data cutoff. These findings were accompanied by a deep molecular remission in the majority of patients as assessed by serial TP53 analysis. No dose-limiting toxicities have been experience

Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II study of APR 2462.12.2018 18:00Pressmeddelande

STOCKHOLM, December 2, 2018. Karolinska Development's portfolio company Aprea Therapeutics today presented positive clinical results for its drug candidate APR 246 at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego, US. An Overall Response Rate of 95% and a Complete Remission (CR) rate of 70% were achieved in an ongoing Phase I/II combination study of APR 246 and azacitidine (AZA) for the treatment of TP53 mutated Myelodysplastic Syndrome (MDS). No dose-limiting toxicities have been observed. Based on these encouraging data, Aprea intends to progress APR 246 into a Phase III study in the near future. The results presented at the ASH meeting is based on 20 patients with TP53 mutated MDS. The overall response rate was 95%, and 14 (70%) patients achieved a complete remission at data cutoff. These findings were accompanied by a deep molecular remission in the majority of patients as assessed by serial TP53 analysis. No dose-limiting toxicities have been experience

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum